ArticleFrontiers in veterinary science2025
Commercial amniotic membrane extract eye drops for canine SCCED: a retrospective clinical evaluation.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to evaluate the efficacy of amniotic membrane extract eye drops (AMEED) in promoting the healing rate of SCCED after cotton-tip debridement (CTD) in dogs. Methods: A retrospective review was conducted on the medical records of dogs with SCCED from October 2021 to December 2024. Cases treated with AMEED following CTD (AMEED group), as well as those treated with CTD alone (CTD group), were selected for further evaluation. Data analyzed included age, sex, breed, medical therapies and procedures used, time to healing, performance of a second procedure, and complications. Results: A total number of 20 eyes from 18 dogs were included in the analysis. Eleven eyes of 10 dogs were in the CTD group, whereas nine eyes of eight dogs were in the AMEED group. The healing rates were 27.2% (3/11) in the CTD group and 77.8% (7/9) in the AMEED group following a single CTD procedure. The mean time of healing following a single CTD procedure was 16.6 days (range: 11-21 days) in the AMEED group and 10.6 days (range: 7-14 days) in the CTD group, respectively. The longer healing time in the AMEED group may be due to more chronic cases and the presence of corneal granulation tissue compared to the CTD group. A second procedure was performed on two eyes in the AMEED group and five eyes in the CTD group that failed to heal after one procedure. For the eyes that healed in both groups, no complications were observed. Conclusion: Topical therapy with AMEED is a safe and effective adjuvant treatment for canine SCCED. AMEED may be preferred in situations where more invasive procedures are less favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.